Translational Development Acquisition Corp. Warrants financials
$1.50−1.76%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $7.5M | — | — |
| Gross profit | $0.00 | $4.5M | — | — |
| Gross margin | — | 60.4% | — | — |
| Operating income | -$944.5K | -$3.7M | -$1.1M | -$699.3K |
| Net income | $6.4M | -$5.8M | -$443.7K | -$476.1K |
| Net margin | — | −77.9% | — | — |
| Diluted EPS | $0.29 | $-2.60 | $-0.60 | $-0.80 |
| EBITDA | -$944.5K | -$2.2M | -$1.1M | -$699.3K |
| Operating cash flow | -$608.4K | $4.7M | -$1.5M | -$603.7K |
| Free cash flow | -$608.4K | $4.7M | — | — |
| Diluted shares | 21.9M | 2.3M | 0.7M | 0.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $29.8K | $3.8M | $55.5K | $1.3M |
| Short-term investments | $0.00 | — | — | — |
| Total debt | $200.0K | $21.8M | $0.00 | $0.00 |
| Total assets | $181.7M | $50.7M | $74.5M | $209.1M |
| Total liabilities | $6.6M | $34.1M | $6.1M | $6.0M |
| Shareholders' equity | -$6.5M | $16.6M | $5.0M | $5.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology